Abstract:Background: Risk stratification in Brugada syndrome (BrS) is based on the occurrence of dynamic factors, such as unexplained syncope and documentation of spontaneous type 1 pattern. At odds with other channelopathies, the role of nonmodifiable risk factors such as sex or genetics remains uncertain. Objectives: This study aims to identify nonmodifiable risk factors for the occurrence of life-threatening arrhythmic events (LAEs) and define their clinical utility. Methods: Clinical and genetic data from consecutive, unrelated Italian patients with Brugada syndrome screened on the sodium voltage-gated channel alpha subunit 5 (SCN5A) gene and 3 pivotal single-nucleotide variations (formerly single-nucleotide polymorphisms) associated with BrS (rs11708996, rs10428132, and rs9388451) were analyzed using multivariable Cox proportional hazards model. Results: In 2,182 unrelated patients with BrS (81% males; median age at diagnosis: 41.6 years [Q1-Q3: 33.4-50.3 years]), male sex (HR: 3.6; 95% CI: 1.9-6.9; P = 0.0001), missense SCN5A mutations in BrS-enriched domains (HR: 2.3; 95% CI: 1.2-4.3; P = 0.008), nonmissense SCN5A mutations (HR: 3.2; 95% CI: 1.8-5.7; P < 0.001), and polygenic risk score for BrS (HR: 1.3; 95% CI: 1.0-1.6; P = 0.041) were all independently associated with a significantly higher risk of a first LAE since birth. Based on these results, we derived the nonmodifiable risk of each patient with BrS, and the division of nonmodifiable risk into tertiles identified 3 distinct risk profiles. In an analysis at follow-up, nonmodifiable risk was independently associated with LAE at follow-up (HR: 1.8; 95% CI: 1.1-2.7; P = 0.014), alongside classical predictors including: history of LAE before diagnosis (HR: 13.8; 95% CI: 8.1-23.7; P < 0.0001), history of unexplained syncope before diagnosis (HR: 4.1; 95% CI: 2.4-6.8; P < 0.0001), and spontaneous type 1 pattern at diagnosis (HR: 2.1; 95% CI: 1.2-3.8; P = 0.010). The model was internally validated, and we derived the equation permitting to calculate the granular 5-year risk of experiencing an LAE at follow-up for each patient with BrS, which may be used to facilitate clinical decision-making. Conclusions: Our data show that male sex, type of SCN5A mutation, and polygenic risk score for BrS define the nonmodifiable risk of each patient with BrS. Nonmodifiable risk is independently associated with LAE, regardless of symptoms or pattern type.

Novelties in Brugada Syndrome: Complex Genetics, Risk Stratification, and Catheter Ablation

Patient-Specific and Genome-Edited Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Brugada Syndrome

Genetic and Molecular Mechanisms in Brugada Syndrome

Brugada Syndrome: From Molecular Mechanisms and Genetics to Risk Stratification

Long-Term Outcomes of Brugada Substrate Ablation: A Report from BRAVO (brugada Ablation of VF Substrate Ongoing Multicenter Registry).

Present Status of Brugada Syndrome: JACC State-of-the-Art Review

Novel Therapeutic Strategies for the Management of Ventricular Arrhythmias Associated with the Brugada Syndrome

Brugada Syndrome: Clinical, Genetic, Molecular, Cellular, and Ionic Aspects

Patient-specific Ipsc-Derived Cardiomyocytes Reveal Aberrant Activation of Wnt/β-catenin Signaling in SCN5A-related Brugada Syndrome

Brugada Syndrome: Focus for the General Pediatrician

Brugada syndrome: current clinical aspects and risk stratification

Ablation for the treatment of Brugada syndrome: current status and future prospects

Prediction and Prevention of Sudden Death in the Brugada Syndrome

Pathogenesis and Management of Brugada Syndrome: Recent Advances and Protocol for Umbrella Reviews of Meta-Analyses in Major Arrhythmic Events Risk Stratification

Characterization of the Epicardial Substrate for Catheter Ablation of Brugada Syndrome.

Electrophysiological patterns and structural substrates of Brugada syndrome: Critical appraisal and computational analyses

Brugada syndrome: identification of subjects at risk and therapy

Catheter ablation as an adjunctive therapy to ICD implantation in Brugada Syndrome

Efficacy and safety of catheter ablation for Brugada syndrome: an updated systematic review

SCN5A gene variants and arrhythmic risk in Brugada syndrome: An updated systematic review and meta-analysis

Nonmodifiable Risk Factors Predict Outcomes in Brugada Syndrome